|
1.
|
Nelson WG: Prostate cancer prevention.
Curr Opin Urol. 17:157–167. 2007. View Article : Google Scholar
|
|
2.
|
Eble JN, Sauter G, Epstein JI and
Sesterhenn IA: Pathology and Genetics of Tumours of the Urinary
System and Male Genital Organs; World Health Organization
Classification of Tumours. International Agency for Research on
Cancer (IARC) Press; Lyon: 2004
|
|
3.
|
Parkin DM: Global cancer statistics in the
year 2000. Lancet Oncol. 2:533–543. 2001.PubMed/NCBI
|
|
4.
|
Argilés JM, Meijsing SH, Pallarés-Trujillo
J, Guirao X and López-Soriano FJ: Cancer cachexia: a therapeutic
approach. Med Res Rev. 1:83–101. 2001.
|
|
5.
|
Tisdale MJ: Biology of cachexia. J Natl
Cancer Inst. 89:1763–1773. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Davis MP and Dickerson D: Cachexia and
anorexia: cancer’s covert killer. Support Care Cancer. 8:180–187.
2000.
|
|
7.
|
Smith KC, Bateman AC, Fussell HM and
Howell WM: Cytokine gene polymorphisms and breast cancer
susceptibility and prognosis. Eur J Immunogenet. 31:167–173. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Chavey C, Bibeau F, Gourgou-Bourgade S,
Burlinchon S, Boissière F, Laune D, Roques S and Lazennec G:
Oestrogen receptor-negative breast cancers exhibit high cytokine
content. Breast Cancer Res. 9:R152007. View
Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Suzuki S, Mita S, Kamohara H, Sakamoto K,
Ishiko T and Ogawa M: IL-6 and IFN-gamma regulation of IL-10
production by human colon carcinoma cells. Int J Oncol. 18:581–586.
2001.PubMed/NCBI
|
|
10.
|
Szaflarska A, Szczepanik A, Siedlar M,
Czupryna A, Sierzega M, Popiela T and Zembala M: Preoperative
plasma level of IL-10 but not of proinflammatory cytokines is an
independent prognostic factor in patients with gastric cancer.
Anticancer Res. 29:5005–5012. 2009.PubMed/NCBI
|
|
11.
|
Kuroda K, Nakashima J, Kanao K, Kikuchi E,
Miyajima A, Horiguchi Y, Nakagawa K, Oya M, Ohigashi T and Murai M:
Interleukin 6 is associated with cachexia in patients with prostate
cancer. Urology. 69:113–117. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Tisdale MJ: New cachexic factors. Curr
Opin Clin Nutr Metab Care. 3:253–256. 1998. View Article : Google Scholar
|
|
13.
|
Nakashima J, Tachibana M, Ueno M, Miyajima
A, Baba S and Murai M: Association between tumor necrosis factor in
serum and cachexia in patients with prostate cancer. Clin Cancer
Res. 7:1743–1748. 1998.PubMed/NCBI
|
|
14.
|
Pfitzenmaier J, Vessella R, Higano CS,
Noteboom JL, Wallace D Jr and Corey E: Elevation of cytokine levels
in cachectic patients with prostate carcinoma. Cancer.
97:1211–1216. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Filella X, Alcover J, Zarco MA, Beardo P,
Molina R and Ballesta AM: Analysis of type T1 and T2 cytokines in
patients with prostate cancer. Prostate. 44:271–274. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Wang M, Hu Y and Stearns ME: A novel IL-10
signalling mechanism regulates TIMP-1 expression in human prostate
tumour cells. Br J Cancer. 88:1605–1614. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Vindrieux D, Escobar P and Lazennec G:
Emerging roles of chemokines in prostate cancer. Endocr Relat
Cancer. 3:663–673. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Giri D, Ozen M and Ittmann M:
Interleukin-6 is an autocrine growth factor in human prostate
cancer. Am J Pathol. 159:2159–2165. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Bouraoui Y, Ricote M, García-Tuñón I,
Rodriguez-Berriguete G, Touffehi M, Rais NB, Fraile B, Paniagua R,
Oueslati R and Royuela M: Pro-inflammatory cytokines and
prostate-specific antigen in hyperplasia and human prostate cancer.
Cancer Detect Prev. 32:23–32. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Berry SJ, Coffey DS, Walsh PC and Ewing
LL: The development of human benign prostatic hyperplasia with age.
J Urol. 132:474–479. 1984.PubMed/NCBI
|
|
21.
|
Barnes PJ: The cytokine network in asthma
and chronic obstructive pulmonary disease. J Clin Invest.
118:3546–3556. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Kim SJ, Uehara H, Karashima T, McCarty M,
Shih N and Fidler IJ: Expression of interleukin-8 correlates with
angiogenesis, tumorigenicity, and metastasis of human prostate
cancer cells implanted orthotopically in nude mice. Neoplasia.
3:33–42. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Inoue K, Slaton JW, Eve BY, Kim SJ,
Perrotte P, Balbay MD, Yano S, Bar-Eli M, Radinsky R, Pettaway CA
and Dinney CP: Interleukin 8 expression regulates tumorigenicity
and metastases in androgen-independent prostate cancer. Clin Cancer
Res. 6:2104–2119. 2000.PubMed/NCBI
|
|
24.
|
Gelin J, Moldawer LL, Lönnroth C, Sherry
B, Chizzonite R and Lundholm K: Role of endogenous tumor necrosis
factor α and interleukin 1 for experimental tumor growth and the
development of cancer cachexia. Cancer Res. 51:415–421. 1991.
|
|
25.
|
Fandrey J and Jelkmann WE: Interleukin-1
and tumor necrosis factor α inhibit erythropoietin production in
vitro. Ann NY Acad Sci. 628:250–255. 1991.
|
|
26.
|
Del Vecchio M, Bajetta E, Canova S, Lotze
MT, Wesa A, Parmiani G and Anichini A: Interleukin-12: Biological
properties and clinical application. Clin Cancer Res. 13:4677–4685.
2007.PubMed/NCBI
|
|
27.
|
Sangro B, Melero I, Qian C and Prieto J:
Gene therapy of cancer based on interleukin 12. Currt Gene Ther.
5:573–581. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Mocellin S, Marincola FM and Young HA:
Interleukin-10 and the immune response against cancer: a
counterpoint. J Leukoc Biol. 78:1043–1051. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Quatan N, Meyer B, Bailey M and Pandha H:
Persistently high levels of immunosuppressive cytokines in patients
after radical prostatectomy. Prostate Cancer Prostatic Dis.
9:420–425. 2006. View Article : Google Scholar : PubMed/NCBI
|
